



Attention Utah Medicaid Pharmacy Providers

Palivizumab End of Season Notification

Utah rates of respiratory syncytial virus (RSV) and bronchiolitis cases are decreasing. Once RSV cases decline, the use of palivizumab is no longer indicated. As a result, Utah is coming to an official close of the RSV season in alignment with our community partners.

Effective Sunday, February 12, 2023, in coordination with Intermountain Health Pediatric Infectious Disease, Medicaid will discontinue the use of palivizumab for RSV prophylaxis in high-risk pediatric patients. Fee-for-Service pharmacy prior authorizations have been updated to reflect this end date.

For additional information or questions related to pharmacy prior authorizations, contact Utah Medicaid at 801-538-6155 option 3, 3, 2. Thank you to all for your efforts in protecting young children from RSV hospitalizations!